INTRODUCTION
The endoplasmic reticulum (ER) is an intracellular organelle where proteins destined for the extracellular space, plasma membrane, and the exo/endocytic compartments are folded and assembled. [1] [2] [3] ER stress, represented by the accumulation of unfolded or misfolded proteins in the ER lumen, is known to induce the unfolded protein response (UPR), an intracellular stress signaling pathway from the ER which alters transcriptional and translational programs within stressed cells. A number of biochemical stimuli or pathophysiological processes, such as perturbation in calcium homeostasis, elevated secretory protein synthesis, overloading of cholesterol or lipids, hyperhomocysteinemia, nutrient deprivation, or infection with pathogenic organisms, can disrupt ER homeostasis and subsequently lead to UPR activation. [3, 4] The UPR is orchestrated by transcriptional activation of multiple genes that are mediated by the protein kinase/endoribonuclease IRE1 (ER-to-nucleus signaling 1, also called ERN1), the b-ZiP transcription factor ATF6 (activating transcription factor 6), a general decrease in translation initiation, and the selective translation of specific mRNAs mediated by the protein kinase PERK (PKR-like ER kinase). [1, 5] In particular, IRE1, the most conserved transducer of UPR signaling, plays a key role in aiding cells to adapt to and survive ER stress conditions. Indeed, IRE1 has been implicated in many physiological processes and the development of complex human diseases.
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is considered the hepatic manifestation of metabolic syndrome. [6, 7] NAFLD is characterized by excessive hepatic lipid accumulation in the absence of significant ethanol consumption, viral infection, or other specific etiologies. Nonalcoholic steatohepatitis (NASH), the advanced stage of NAFLD, is found in a substantial fraction of individuals with fatty livers who develop chronic cell injury due to excess lipid deposition. [7] The livers of NASH patients exhibit hepatic inflammation, fibrosis, and liver cell death in addition to steatosis. In recent years, the functional involvement of ER stress and UPR in NAFLD has been largely studied. However, there is controversy in regard to whether the UPR signaling is upregulated or downregulated in the livers of NAFLD or NASH patients or animal models. In this study, we investigated the expression profiles of the primary UPR transducer IRE1 in the livers of human NASH patients.
METHODS
The analyses presented in this article were conducted on datasets obtained from the National Institutes of Health (NIH)'s National Center for Biotechnology Information Gene Expression Omnibus (GEO) Database (www.ncbi.nlm.nih.gov/geo/). Each dataset obtained and analyzed from this database consisted of mRNA microarray data taken from liver biopsies from individual human patients. Within each dataset, patient groups were separated based on their clinical liver diagnosis. We performed multiple comparisons tests to analyze variations in the expression levels of IRE1 (ERN1). Table 1 lists the analyses that were performed to understand the associations of variations in the expression of IRE1 gene with NASH.
All statistical tests were performed in R software (R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria). Wilcoxon signed-rank tests were performed to test for significant variations in gene expression levels between the two patient groups involved in this study (non-NASH and NASH). In all comparison tests, P < 0.05 was considered to be statistically significant.
RESULTS
We examined the expression levels of the primary UPR transducer IRE1 in the livers of human NASH patients and non-NASH individuals based on the microRNA datasets of public domain. The mRNA microarray data showing total gene expression were obtained from the GSE83452 dataset from the GEO database. Specifically, human liver biopsy samples were obtained from a total of 152 obese patients, 148 of whom were diagnosed as either non-NASH (n = 44) or NASH (n = 104) [8] [ Table 1 ].
Wilcoxon signed-rank tests were performed to compare gene expression levels in patients diagnosed with NASH with those without NASH, by testing the null hypothesis that gene expression levels in the obese patients without NASH and the obese patients with NASH are equal. As shown in Figure 1 , there was very strong evidence that IRE1 mRNA expression levels are significantly decreased in the NASH livers in comparison to non-NASH livers (P < 0.001).
DISCUSSION
The involvement of UPR in the pathogenesis of NAFLD has been intensively investigated. However, in the past 20 years, a number of conflicting studies in regard to activation of the UPR in the livers of NAFLD or NASH patients or animal models have been published. Indeed, many reported that the UPR signaling was activated to act as a driving force in the progression of NASH. In contrast, an increasing number of studies showed that UPR, particularly the IRE1-mediated UPR, was repressed in the livers of NASH patients or animal models. [9] [10] [11] In this study, based on the gene expression profiles in the livers of human NASH patients, we demonstrated that the expression levels of IRE1 were indeed decreased in the livers of human obese patients with NASH, compared to those of obese patients without NASH [ Figure 1 ]. Although the expression levels of IRE1 may not be necessarily consistent with IRE1 RNase activity, our analysis result is consistent with the role of IRE1-mediated UPR in preserving cellular homeostasis and functions and in protecting organisms from injuries caused by stressors. However, we should note that the simple comparison performed in this study did not include additional factors; for example, the age factor. It is possible that UPR may be activated in a particular stage of NASH where the pathological condition causes ER stress and UPR activation in the liver. This question warrants further investigation of UPR involvement in NASH with the analysis of additional human NASH gene expression datasets.
